{
    "2021-10-22": [
        [
            {
                "time": "",
                "original_text": "面临多重困境的恒瑞医药，凭什么重夺“医药一哥”宝座？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "多重困境",
                        "医药一哥"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "24家药企披露前三季度“成绩单”，恒瑞、天宇药业等6家下滑！",
                "features": {
                    "keywords": [
                        "药企",
                        "前三季",
                        "成绩单",
                        "恒瑞",
                        "天宇药业",
                        "下滑"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "史上罕见！三季报后613家机构千人电话会议调研迈瑞医疗，公司回应多个热点问题",
                "features": {
                    "keywords": [
                        "迈瑞医疗",
                        "三季报",
                        "机构调研",
                        "热点问题"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "迈瑞医疗接受473家机构调研",
                "features": {
                    "keywords": [
                        "迈瑞医疗",
                        "机构调研"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "迈瑞医疗（300760.SZ）：业绩稳步增长，“创新研发+并购外延”拓宽业务边界",
                "features": {
                    "keywords": [
                        "迈瑞医疗",
                        "业绩增长",
                        "创新研发",
                        "并购外延"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中信建投医药大健康团队最新研究",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药大健康",
                        "研究"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "险资三季度首批重仓股曝光 险资三季度减持银行地产股加仓新能源与“专精特新” 减持股份数量",
                "features": {
                    "keywords": [
                        "险资",
                        "三季度",
                        "重仓股",
                        "减持",
                        "银行地产",
                        "加仓",
                        "新能源",
                        "专精特新"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "新能源",
                        "专精特新"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}